1,239
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Urinary orosomucoid is associated with diastolic dysfunction and carotid arteriopathy in the general population. Cross-sectional data from the Tromsø study

, , , , , , & show all
Pages 148-156 | Received 15 Nov 2021, Accepted 13 May 2022, Published online: 02 Jun 2022

References

  • Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;385(9963):148–171.
  • Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88(2):451–487.
  • Comper WD, Haraldsson B, Deen WM. Resolved: normal glomeruli filter nephrotic levels of albumin. J Am Soc Nephrol. 2008;19(3):427–432.
  • Fried LF, Lewis J. Albuminuria is not an appropriate therapeutic target in patients with CKD: the con view. Clin J Am Soc Nephrol. 2015;10(6):1089–1093.
  • Matsushita K, Coresh J, Sang Y, CKD Prognosis Consortium, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative Meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514–525.
  • Fournier T, Medjoubi NN, Porquet D. Alpha-1-acid glycoprotein. Biochim Biophys Acta. 2000;1482(1-2):157–171.
  • Varghese SA, Powell TB, Budisavljevic MN, et al. Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol. 2007;18(3):913–922.
  • Salmon AH, Ferguson JK, Burford JL, et al. Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol. 2012;23(8):1339–1350.
  • Padberg JS, Wiesinger A, di Marco GS, et al. Damage of the endothelial glycocalyx in chronic kidney disease. Atherosclerosis. 2014;234(2):335–343.
  • Fandino-Vaquero R, Fernandez-Trasancos A, Alvarez E, et al. Orosomucoid secretion levels by epicardial adipose tissue as possible indicator of endothelial dysfunction in diabetes mellitus or inflammation in coronary artery disease. Atherosclerosis. 2014;235(2):281–288.
  • Kustan P, Szirmay B, Horvath-Szalai Z, et al. Urinary orosomucoid: validation of an automated immune turbidimetric test and its possible clinical use. Biochem Med (Zagreb). 2016;26(3):421–430.
  • Christiansen MS, Blirup-Jensen S, Foged L, et al. A particle-enhanced turbidimetric immunoassay for quantitative determination of orosomucoid in urine: development, validation and reference values. Clin Chem Lab Med. 2004;42(10):1168–1177.
  • Hou LN, Li F, Zeng QC, et al. Excretion of urinary orosomucoid 1 protein is elevated in patients with chronic heart failure. PloS One. 2014;9(9):e107550.
  • Kustán P, Kőszegi T, Miseta A, et al. Urinary orosomucoid a potential marker of inflammation in psoriasis. Int J Med Sci. 2018;15(11):1113–1117.
  • Park YJ, Yoo SA, Hwang D, et al. Identification of novel urinary biomarkers for assessing disease activity and prognosis of rheumatoid arthritis. Exp Mol Med. 2016;48:e211.
  • Jiang H, Guan G, Zhang R, et al. Increased urinary excretion of orosomucoid is a risk predictor of diabetic nephropathy. Nephrology (Carlton, Vic. 2009;14(3):332–337.
  • Christiansen MS, Hommel E, Magid E, et al. Orosomucoid in urine predicts cardiovascular and over-all mortality in patients with type II diabetes. Diabetologia. 2002;45(1):115–120.
  • Christiansen MS, Hommel E, Magid E, et al. Orosomucoid in urine is a powerful predictor of cardiovascular mortality in normoalbuminuric patients with type 2 diabetes at five years of follow-up. Diabetologia. 2005;48(2):386–393.
  • Nemeth B, Peter I, Boncz I, et al. Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients? TCRM. 2019;ume 15:831–837.
  • Lorenz MW, Bickel H, Bots ML, PROG-IMT Study Group, et al. Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): rationale and design of a Meta-analysis project. Am Heart J. 2010;159(5):730–736 e732.
  • Mathiesen EB, Johnsen SH, Wilsgaard T, et al. Carotid plaque area and intima-media thickness in prediction of first-ever ischemic stroke: a 10-year follow-up of 6584 men and women: the Tromsø Study. Stroke. 2011;42(4):972–978.
  • Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263–271.
  • Bedirian R, Neves MF, Oigman W, et al. Correlation between diastolic function and endothelial function in patients with type 2 diabetes and hypertension. Open Cardiovasc Med J. 2016;10:212–220.
  • Jacobsen BK, Eggen AE, Mathiesen EB, et al. Cohort profile: the tromso study. Int J Epidemiol. 2012;41(4):961–967.
  • Levey AS, Stevens LA, Schmid CH, for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration), et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
  • Vittinghus E. Preanalytical handling of stored urine samples, and measurement of beta 2-microglobulin, orosomucoid, albumin, transferrin and immunoglobulin G in urine by enzyme-linked immunosorbent assays (ELISA). Scand J Clin Lab Invest. 1990;50(8):843–849.
  • Kronborg CS, Allen J, Vittinghus E, et al. Pre-symptomatic increase in urine-orosomucoid excretion in pre-eclamptic women. Acta Obstet Gynecol Scand. 2007;86(8):930–937.
  • Eggen AE, Mathiesen EB, Wilsgaard T, et al. The sixth survey of the tromso study (tromso 6) in 2007-08: collaborative research in the interface between clinical medicine and epidemiology: study objectives, design, data collection procedures, and attendance in a multipurpose population-based health survey. Scand J Public Health. 2013;41(1):65–80.
  • Nagueh SF, Smiseth OA, Appleton CP, Houston, Texas; Oslo, Norway; Phoenix, Arizona; Nashville, Tennessee; Hamilton, Ontario, Canada; Uppsala, Sweden; Ghent and Liège, Belgium; Cleveland, Ohio; Novara, Italy; Rochester, Minnesota; Bucharest, Romania; and St. Louis, Missouri, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the uropean society of echocardiography and the uropean association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2016;17(12):1321–1360.
  • Stensland-Bugge E, Bønaa KH, Joakimsen O. Reproducibility of ultrasonographically determined intima-media thickness is dependent on arterial wall thickness. The Tromsø Study. Stroke. 1997;28(10):1972–1980.
  • Fosse E, Johnsen SH, Stensland-Bugge E, et al. Repeated visual and computer-assisted carotid plaque characterization in a longitudinal population-based ultrasound study: the Tromsø study. Ultrasound Med Biol. 2006;32(1):3–11.
  • Gerdts E, Regitz-Zagrosek V. Sex differences in cardiometabolic disorders. Nat Med. 2019;25(11):1657–1666.
  • van der Velde M, Matsushita K, Coresh J, Chronic Kidney Disease Prognosis Consortium, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative Meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1341–1352.
  • Solbu MD, Kronborg J, Jenssen TG, et al. Albuminuria, metabolic syndrome and the risk of mortality and cardiovascular events. Atherosclerosis. 2009;204(2):503–508.
  • Mule G, Castiglia A, Cusumano C, et al. Subclinical kidney damage in hypertensive patients: a renal window opened on the cardiovascular system. Focus on microalbuminuria. Adv Exp Med Biol. 2017;956:279–306.
  • Magid E, Guldager H, Hesse D, et al. Monitoring urinary orosomucoid in acute inflammation: observations on urinary excretion of orosomucoid, albumin, alpha1-microglobulin, and IgG. Clin Chem. 2005;51(11):2052–2058.
  • Kustan P, Horvath-Szalai Z, Muhl D. Nonconventional markers of sepsis. EJIFCC. 2017;28(2):122–133.
  • Kustan P, Szirmay B, Horvath-Szalai Z, et al. Urinary orosomucoid: a novel, early biomarker of sepsis with promising diagnostic performance. Clin Chem Lab Med. 2017;55(2):299–307.
  • Szirmay B, Tarnok A, Sarlos P, et al. Elevated urinary orosomucoid excretion as a novel biomarker in crohn’s disease. Eur J Clin Invest. 2018;49(3):e13054.
  • Li F, Yu Z, Chen P, et al. The increased excretion of urinary orosomucoid 1 as a useful biomarker for bladder cancer. Am J Cancer Res. 2016;6(2):331–340.
  • Jerebtsova M, Saraf SL, Soni S, et al. Urinary orosomucoid is associated with progressive chronic kidney disease stage in patients with sickle cell anemia. Am J Hematol. 2018;93(4):E107–E109.
  • El-Beblawy NM, Andrawes NG, Ismail EA, et al. Serum and urinary orosomucoid in young patients with type 1 diabetes: a link between inflammation, microvascular complications, and subclinical atherosclerosis. Clin Appl Thromb Hemost. 2016;22(8):718–726.
  • Valente MAE, Damman K, Dunselman PHJM, et al. Urinary proteins in heart failure. Prog Cardiovasc Dis. 2012;55(1):44–55.
  • Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med. 2017;376(9):897.
  • Gladden JD, Chaanine AH, Redfield MM. Heart failure with preserved ejection fraction. Annu Rev Med. 2018;69:65–79.
  • Furtner M, Kiechl S, Mair A, et al. Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. Eur Heart J. 2005;26(3):279–287.
  • Jørgensen L, Jenssen T, Johnsen SH, et al. Albuminuria as risk factor for initiation and progression of carotid atherosclerosis in non-diabetic persons: the tromsø study. Eur Heart J. 2007;28(3):363–369.